Subject(s)
Biosensing Techniques , National Institutes of Health (U.S.) , Neoplasms , Research , Space Flight , United States National Aeronautics and Space Administration , Biomarkers , Biomarkers, Tumor , Miniaturization , Neoplasms/diagnosis , Neoplasms/prevention & control , Neoplasms/therapy , Spacecraft , United StatesABSTRACT
Deletions of 3p25, gains of chromosomes 7 and 10, and isochromosome 17q are known cytogenetic aberrations in sporadic renal cell carcinoma (RCC). In addition, a majority of RCCs have loss of heterozygosity (LOH) of the Von Hippel-Lindau (VHL) gene located at chromosome band 3p25. Patients who inherit a germline mutation of the VHL gene can develop multifocal RCCs and other solid tumors, including malignancies of the pancreas, adrenal medulla, and brain. VHL tumors follow the two-hit model of tumorigenesis, as LOH of VHL, a classic tumor suppressor gene, is the critical event in the development of the neoplastic phenotype. In an attempt to define the cytogenetic aberrations from early tumors to late RCC further, we applied spectral karyotyping (SKY) to 23 renal tumors harvested from 6 unrelated VHL patients undergoing surgery. Cysts and low-grade solid lesions were near-diploid and contained 1-2 reciprocal translocations, dicentric chromosomes, and/or isochromosomes. A variety of sole numerical aberrations included gains of chromosomes 1, 2, 4, 7, 10, 13, 21, and the X chromosome, although no tumors had sole numerical losses. Three patients shared a breakpoint at 2p21-22, and three others shared a dicentric chromosome 9 or an isochromosome 9q. In contrast to the near-diploidy of the low-grade lesions, a high-grade lesion and its nodal metastasis were markedly aneuploid, revealed loss of VHL by fluorescence in situ hybridization (FISH), and contained recurrent unbalanced translocations and losses of chromosome arms 2q, 3p, 4q, 9p, 14q, and 19p as demonstrated by comparative genomic hybridization (CGH). By combining SKY, CGH, and FISH of multiple tumors from the same VHL kidney, we have begun to identify chromosomal aberrations in the earliest stages of VHL-related renal cell tumors. Our current findings illustrate the cytogenetic heterogeneity of different VHL lesions from the same kidney, which supports the multiclonal origins of hereditary RCCs. Published 2001 Wiley-Liss, Inc.
Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , von Hippel-Lindau Disease/genetics , Adult , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Chromosome Aberrations/genetics , Disease Progression , Female , Humans , In Situ Hybridization, Fluorescence/methods , Karyotyping/methods , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Male , Middle Aged , Translocation, Genetic/genetics , Tumor Cells, Cultured , von Hippel-Lindau Disease/pathology , von Hippel-Lindau Disease/surgeryABSTRACT
Mutations of the VHL tumor suppressor gene occur in patients with VHL disease and in the majority of sporadic clear cell renal carcinomas (VHL(-/-) RCC). Loss of VHL protein function is associated with constitutive expression of mRNAs encoding hypoxia-inducible proteins, such as vascular endothelial growth factor. Overproduction of angiogenic factors might explain why VHL(-/-) RCC tumors are so highly vascularized, but whether this overproduction is sufficient for oncogenesis still remains unknown. In this report, we examined the activity of transforming growth factor-alpha (TGF-alpha), another VHL-regulated growth factor. We show that TGF-alpha mRNA and protein are hypoxia-inducible in VHL(-/-) RCC cells expressing reintroduced VHL. In addition to its overexpression by VHL(-/-) RCC cells, TGF-alpha can also act as a specific growth-stimulatory factor for VHL(-/-) RCC cells expressing reintroduced wild-type VHL, as well as primary renal proximal tubule epithelial cells, the likely site of origin of RCC. This role is in contrast to those of other growth factors overexpressed by VHL(-/-) RCC cells, such as vascular endothelial growth factor and TGF-beta1, which do not stimulate RCC cell proliferation. A TGF-alpha-specific antisense oligodeoxynucleotide blocked TGF-alpha production in VHL(-/-) RCC cells, which led to the dependence of those cells on exogenous growth factors to sustain growth in culture. Growth of VHL(-/-) RCC cells was also significantly reduced by a drug that specifically inhibits the epidermal growth factor receptor, the receptor through which TGF-alpha stimulates proliferation. These results suggest that the generation of a TGF-alpha autocrine loop as a consequence of VHL inactivation in renal proximal tubule epithelial cells may provide the uncontrolled growth stimulus necessary for the initiation of tumorigenesis.
Subject(s)
Genes, Tumor Suppressor , Ligases , Proteins/physiology , Transforming Growth Factor alpha/physiology , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Adenocarcinoma, Clear Cell , Cell Division/drug effects , Cell Hypoxia , Enzyme Inhibitors/pharmacology , ErbB Receptors/antagonists & inhibitors , Gene Expression Regulation , Growth Substances/pharmacology , Humans , Insulin/pharmacology , Kidney Neoplasms , Oligodeoxyribonucleotides, Antisense , Proteins/genetics , Quinazolines/pharmacology , Selenium/pharmacology , Transferrin/pharmacology , Transforming Growth Factor alpha/genetics , Transforming Growth Factor alpha/metabolism , Transforming Growth Factor alpha/pharmacology , Tumor Cells, Cultured , Tyrphostins/pharmacology , Von Hippel-Lindau Tumor Suppressor Protein , von Hippel-Lindau DiseaseSubject(s)
Cytogenetic Analysis , Genome, Human , Human Genome Project , Physical Chromosome Mapping/methods , Chromosomes, Bacterial/genetics , Chromosomes, Human, Pair 22/genetics , Chromosomes, Human, Pair 7/genetics , Cloning, Molecular , Contig Mapping , Humans , In Situ Hybridization, Fluorescence , Sequence Tagged SitesSubject(s)
Gene Expression Profiling/methods , Prostatic Neoplasms/genetics , Databases, Factual , Gene Expression , Gene Expression Profiling/statistics & numerical data , Gene Library , Humans , Male , Oligonucleotide Array Sequence Analysis , Pathology, Clinical/methods , Polymorphism, Single NucleotideABSTRACT
von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited cancer syndrome predisposing to a variety of tumor types that include retinal hemangioblastomas, hemangioblastomas of the central nervous system, renal cell carcinomas, pancreatic cysts and tumors, pheochromocytomas, endolymphatic sac tumors, and epididymal cystadenomas [W. M. Linehan et al., J. Am. Med. Assoc., 273: 564-570, 1995; E. A. Maher and W. G. Kaelin, Jr., Medicine (Baltimore), 76: 381-391, 1997; W. M. Linehan and R. D. Klausner, In: B. Vogelstein and K. Kinzler (eds.), The Genetic Basis of Human Cancer, pp. 455-473, McGraw-Hill, 1998]. The VHL gene was localized to chromosome 3p25-26 and cloned [F. Latif et al., Science (Washington DC), 260: 1317-1320, 1993]. Germline mutations in the VHL gene have been detected in the majority of VHL kindreds. The reported frequency of detection of VHL germline mutations has varied from 39 to 80% (J. M. Whaley et al., Am. J. Hum. Genet., 55: 1092-1102, 1994; Clinical Research Group for Japan, Hum. Mol. Genet., 4: 2233-2237, 1995; F. Chen et al., Hum. Mutat., 5: 66-75, 1995; E. R. Maher et al., J. Med. Genet., 33: 328-332, 1996; B. Zbar, Cancer Surv., 25: 219-232, 1995). Recently a quantitative Southern blotting procedure was found to improve this frequency (C. Stolle et al., Hum. Mutat., 12: 417-423, 1998). In the present study, we report the use of fluorescence in situ hybridization (FISH) as a method to detect and characterize VHL germline deletions. We reexamined a group of VHL patients shown previously by single-strand conformation and sequencing analysis not to harbor point mutations in the VHL locus. We found constitutional deletions in 29 of 30 VHL patients in this group using cosmid and P1 probes that cover the VHL locus. We then tested six phenotypically normal offspring from four of these VHL families: two were found to carry the deletion and the other four were deletion-free. In addition, germline mosaicism of the VHL gene was identified in one family. In sum, FISH was found to be a simple and reliable method to detect VHL germline deletions and practically useful in cases where other methods of screening have failed to detect a VHL gene abnormality.
Subject(s)
Gene Deletion , In Situ Hybridization, Fluorescence/methods , von Hippel-Lindau Disease/genetics , Chromosomes, Human, Pair 3 , Family Health , Female , Genetic Testing/methods , Humans , Models, Genetic , Point MutationABSTRACT
Mutations of von Hippel-Lindau disease (VHL) tumor-suppressor gene product (pVHL) are found in patients with dominant inherited VHL syndrome and in the vast majority of sporadic clear cell renal carcinomas. The function of the pVHL protein has not been clarified. pVHL has been shown to form a complex with elongin B and elongin C (VBC) and with cullin (CUL)-2. In light of the structural analogy of VBC-CUL-2 to SKP1-CUL-1-F-box ubiquitin ligases, the ubiquitin ligase activity of VBC-CUL-2 was examined in this study. We show that VBC-CUL-2 exhibits ubiquitin ligase activity, and we identified UbcH5a, b, and c, but not CDC34, as the ubiquitin-conjugating enzymes of the VBC-CUL-2 ubiquitin ligase. The protein Rbx1/ROC1 enhances ligase activity of VBC-CUL-2 as it does in the SKP1-CUL-1-F-box protein ligase complex. We also found that pVHL associates with two proteins, p100 and p220, which migrate at a similar molecular weight as two major bands in the ubiquitination assay. Furthermore, naturally occurring pVHL missense mutations, including mutants capable of forming a complex with elongin B-elongin C-CUL-2, fail to associate with p100 and p220 and cannot exhibit the E3 ligase activity. These results suggest that pVHL might be the substrate recognition subunit of the VBC-CUL-2 E3 ligase. This is also, to our knowledge, the first example of a human tumor-suppressor protein being directly involved in the ubiquitin conjugation system which leads to the targeted degradation of substrate proteins.
Subject(s)
Genes, Tumor Suppressor , Ligases/metabolism , Proteins/metabolism , Tumor Suppressor Proteins , Carrier Proteins/metabolism , Humans , Molecular Weight , Mutation , Protein Binding , Proteins/genetics , Recombinant Proteins/metabolism , Tumor Cells, Cultured , Ubiquitin-Protein Ligases , Ubiquitins/chemistry , Ubiquitins/metabolism , Von Hippel-Lindau Tumor Suppressor ProteinABSTRACT
The Mammalian Gene Collection (MGC) project is a new effort by the NIH to generate full-length complementary DNA (cDNA) resources. This project will provide publicly accessible resources to the full research community. The MGC project entails the production of libraries, sequencing, and database and repository development, as well as the support of library construction, sequencing, and analytic technologies dedicated to the goal of obtaining a full set of human and other mammalian full-length (open reading frame) sequences and clones of expressed genes.
Subject(s)
Gene Library , Genome, Human , Genome , Mammals/genetics , Sequence Analysis, DNA , Animals , Base Sequence , Computational Biology , DNA, Complementary , Databases, Factual , Expressed Sequence Tags , Humans , Mice , National Institutes of Health (U.S.) , Private Sector , Public Sector , United StatesSubject(s)
Disease Models, Animal , Neoplasms/genetics , Animals , Humans , Mice , Neoplasms/pathologySubject(s)
National Institutes of Health (U.S.) , Neoplasms/genetics , Chromosome Aberrations , Genome , Humans , Research , United StatesABSTRACT
Loss of function in the von Hippel-Lindau (VHL) tumor suppressor gene occurs in familial and most sporadic renal cell carcinomas (RCCs). VHL has been linked to the regulation of cell cycle cessation (G(0)) and to control of expression of various mRNAs such as for vascular endothelial growth factor. RCC cells express the Met receptor tyrosine kinase, and Met mediates invasion and branching morphogenesis in many cell types in response to hepatocyte growth factor/scatter factor (HGF/SF). We examined the HGF/SF responsiveness of RCC cells containing endogenous mutated (mut) forms of the VHL protein (VHL-negative RCC) with that of isogenic cells expressing exogenous wild-type (wt) VHL (VHL-positive RCC). We found that VHL-negative 786-0 and UOK-101 RCC cells were highly invasive through growth factor-reduced (GFR) Matrigel-coated filters and exhibited an extensive branching morphogenesis phenotype in response to HGF/SF in the three-dimensional (3D) GFR Matrigel cultures. In contrast, the phenotypes of A498 VHL-negative RCC cells were weaker, and isogenic RCC cells ectopically expressing wt VHL did not respond at all. We found that all VHL-negative RCC cells expressed reduced levels of tissue inhibitor of metalloproteinase 2 (TIMP-2) relative to the wt VHL-positive cells, implicating VHL in the regulation of this molecule. However, consistent with the more invasive phenotype of the 786-0 and UOK-101 VHL-negative RCC cells, the levels of TIMP-1 and TIMP-2 were reduced and levels of the matrix metalloproteinases 2 and 9 were elevated compared to the noninvasive VHL-positive RCC cells. Moreover, recombinant TIMPs completely blocked HGF/SF-mediated branching morphogenesis, while neutralizing antibodies to the TIMPs stimulated HGF/SF-mediated invasion in vitro. Thus, the loss of the VHL tumor suppressor gene is central to changes that control tissue invasiveness, and a more invasive phenotype requires additional genetic changes seen in some but not all RCC lines. These studies also demonstrate a synergy between the loss of VHL function and Met signaling.
Subject(s)
Carcinoma, Renal Cell/genetics , Genes, Tumor Suppressor , Hepatocyte Growth Factor/pharmacology , Kidney Neoplasms/genetics , Ligases , Proteins/genetics , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , von Hippel-Lindau Disease/genetics , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/physiopathology , Endopeptidases/metabolism , Extracellular Space/enzymology , Gene Expression , Hepatocyte Growth Factor/antagonists & inhibitors , Hepatocyte Growth Factor/physiology , Humans , Kidney Neoplasms/pathology , Kidney Neoplasms/physiopathology , Neoplasm Invasiveness , Phenotype , Receptor Protein-Tyrosine Kinases/metabolism , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-2/genetics , Tissue Inhibitor of Metalloproteinase-2/metabolism , Tumor Cells, Cultured , Von Hippel-Lindau Tumor Suppressor ProteinABSTRACT
The yeast two-hybrid system is a powerful technique that detects interactions between two proteins and has been useful in identifying new binding partners. However, the system fails to detect protein-protein interactions that require the presence of additional components of a multisubunit complex. Here we demonstrate that the vector YIpDCE1 can be used to express elongins B and C in yeast, and that these proteins form a stable complex that interacts with the von Hippel-Lindau tumor-suppressor gene product (pVHL). Only when pVHL and elongins B and C (VBC) are present does an interaction with the cullin family member, hCUL-2, occur, forming the heterotetrameric pVHL/elongin BC/hCUL-2 complex. This system was then used to map the binding region of hCUL-2 for the VBC complex. The first amino-terminal 108 aa of hCUL-2 are necessary for interaction with the VBC complex. The elongin BC dimer acts as a bridge between pVHL and hCUL-2 because pVHL and hCUL-2 can form distinct complexes with elongins B and C. These results reveal a striking structural resemblance of pVHL/elongin BC/hCUL-2 complex with the E3-like ubiquitin ligase complex SKP1/Cullin/F-box protein with respect to protein composition and sites of interactions. Thus, it seems possible that pVHL/elongin BC/hCUL-2 complex will possess ubiquitin ligase activity targeting specific proteins for degradation by the proteasome.
Subject(s)
Carrier Proteins/metabolism , Cell Cycle Proteins/metabolism , Cullin Proteins , Ligases , Peptide Synthases/metabolism , Proteins/metabolism , Transcription Factors/metabolism , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Binding Sites , Elongin , Genetic Vectors , Peptide Mapping , Polymerase Chain Reaction , Protein Binding , SKP Cullin F-Box Protein Ligases , Schizosaccharomyces , Von Hippel-Lindau Tumor Suppressor ProteinABSTRACT
Mutation of the von Hippel-Lindau tumor suppressor gene (vhl) causes the von Hippel-Lindau cancer syndrome as well as sporadic renal clear cell carcinoma. To pursue our study of the intracellular localization of VHL protein in relation to its function, we fused VHL to the green fluorescent protein (GFP) to produce the VHL-GFP fusion protein. Like VHL, VHL-GFP binds to elongins B and C and Cullin-2 and regulates target gene product levels, including levels of vascular endothelial growth factor and glucose transporter 1. VHL-GFP localizes predominantly to the cytoplasm, with some detectable nuclear signal. Inhibition of transcription by actinomycin D or 5,6-dichlorobenzimidazole riboside (DRB) causes VHL to be redistributed to the nucleus. A cellular fusion assay was used to demonstrate that inhibition of transcription induces a decrease in the nuclear export rate of VHL. The dependence of transcription for trafficking is lost with a deletion of exon 2, a region with a mutation causing a splice defect in the VHL gene in sporadic renal clear cell carcinoma. Addition of a strong nuclear export signal (NES) derived from the Rev protein results in complete nuclear exclusion and abrogates the redistribution of VHL-GFP-NES into the nucleus upon inhibition of transcription. Leptomycin B, which inhibits NES-mediated nuclear export, reverts the distribution of VHL-GFP-NES to that of VHL-GFP and restores sensitivity to actinomycin D and DRB. Uncoupling of VHL-GFP trafficking to transcription either by an exon 2 deletion or fusion to NES abolishes VHL function. We suggest that VHL function requires not only nuclear or cytoplasmic localization, but also exon 2-mediated transcription-dependent trafficking between these two cellular compartments.
Subject(s)
Ligases , Proteins/metabolism , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Animals , Base Sequence , Biological Transport, Active/drug effects , COS Cells , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/metabolism , Cell Fusion , Cell Nucleus/metabolism , Cytoplasm/metabolism , DNA Primers/genetics , Dactinomycin/pharmacology , Genes, Tumor Suppressor , Green Fluorescent Proteins , HeLa Cells , Humans , Kidney Neoplasms/genetics , Kidney Neoplasms/metabolism , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Mutation , Proteins/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transcription, Genetic , Tumor Cells, Cultured , Von Hippel-Lindau Tumor Suppressor Protein , von Hippel-Lindau Disease/genetics , von Hippel-Lindau Disease/metabolismABSTRACT
Although iron is an essential nutrient, it is also a potent cellular toxin, and the acquisition of iron is a highly regulated process in eukaryotes. In yeast, iron uptake is homeostatically regulated by the transcription factor encoded by AFT1. Expression of AFT1-1(up), a dominant mutant allele, results in inappropriately high rates of iron uptake, and AFT1-1(up) mutants grow slowly in the presence of high concentrations of iron. We present evidence that when Aft1-1(up) mutants are exposed to iron, they arrest the cell division cycle at the G1 regulatory point Start. This arrest is dependent on high-affinity iron uptake and does not require the activation of the DNA damage checkpoint governed by RAD9. The iron-induced arrest is bypassed by overexpression of a mutant G1 cyclin, cln3-2, and expression of the G1-specific cyclins Cln1 and Cln2 is reduced when yeast are exposed to increasing amounts of iron, which may account for the arrest. This reduction is not due to changes in transcription of CLN1 or CLN2, nor is it due to accelerated degradation of the protein. Instead, this reduction occurs at the level of Cln2 translation, a recently recognized locus of cell-cycle control in yeast.
Subject(s)
Cyclins/biosynthesis , Fungal Proteins/genetics , Gene Expression Regulation, Fungal , Iron/toxicity , Protein Biosynthesis , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae/cytology , Transcription Factors/genetics , Biological Transport , Fungal Proteins/biosynthesis , G1 Phase/drug effects , Homeostasis , Models, Genetic , Mutation , Saccharomyces cerevisiae/drug effects , Tripeptidyl-Peptidase 1ABSTRACT
The cell wall protects fungi against lysis and determines their cell shape. Alpha-glucan is a major carbohydrate component of the fungal cell wall, but its function is unknown and its synthase has remained elusive. Here, we describe a fission yeast gene, ags1(+), which encodes a putative alpha-glucan synthase. In contrast to the structure of other carbohydrate polymer synthases, the predicted Ags1 protein consists of two probable catalytic domains for alpha-glucan assembly, namely an intracellular domain for alpha-glucan synthesis and an extracellular domain speculated to cross-link or remodel alpha-glucan. In addition, the predicted Ags1 protein contains a multipass transmembrane domain that might contribute to transport of alpha-glucan across the membrane. Loss of Ags1p function in a temperature-sensitive mutant results in cell lysis, whereas mutant cells grown at the semipermissive temperature contain decreased levels of cell wall alpha-glucan and fail to maintain rod shapes, causing rounding of the cells. These findings demonstrate that alpha-glucan is essential for fission yeast morphogenesis.
Subject(s)
Cell Wall , Glucosyltransferases/metabolism , Schizosaccharomyces pombe Proteins , Schizosaccharomyces/enzymology , Amino Acid Sequence , Cloning, Molecular , Glucosyltransferases/genetics , Microscopy, Electron , Molecular Sequence Data , Schizosaccharomyces/cytology , Schizosaccharomyces/ultrastructure , Sequence Homology, Amino AcidABSTRACT
YIpDCE1 (Dual Constitutive Expression), a novel Saccharomyces cerevisiae integrating plasmid, constitutively expresses two genes under the control of separate phosphoglycerol kinase promoters. YIpDCE1 contains the complete ADE2 gene which can be used as a marker for selecting integrants at mutant ade2 loci commonly present in laboratory yeast strains. The YIpDCE1 plasmid can be inserted into the ade2-101 locus of the HF7c strain used in two hybrid screens. Thus it could be useful for analysis of two hybrid interactions that occur in the context of additional protein components (e.g. modifying enzymes such as kinases or phosphatases, or multimeric complexes consisting of three or four distinct protein components). YIpDCE1 has been used to create strains simultaneously overexpressing the permease (FTR1) and oxidase (FET3) components of the yeast high-affinity iron uptake system. This confers constitutive high-affinity iron uptake on the transformed strains, bypassing the normal regulatory mechanisms.
Subject(s)
Ceruloplasmin , Gene Expression Regulation, Fungal , Plasmids/genetics , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae/genetics , Blotting, Northern , Blotting, Southern , Blotting, Western , Carboxy-Lyases/genetics , Carrier Proteins/biosynthesis , Carrier Proteins/genetics , Fungal Proteins/biosynthesis , Fungal Proteins/genetics , Iron/metabolism , Membrane Transport Proteins/biosynthesis , Membrane Transport Proteins/genetics , Molecular Sequence Data , Oxidoreductases/biosynthesis , Oxidoreductases/genetics , Phosphoglycerate Kinase/genetics , Plasmids/chemical synthesis , Saccharomyces cerevisiae/enzymology , Transformation, GeneticABSTRACT
The ability of iron to catalyze formation of reactive oxygen species significantly contributes to its toxicity in cells and animals. Iron uptake and distribution is regulated tightly in mammalian cells, in part by iron regulatory protein 2 (IRP2), a protein that is degraded efficiently by the proteasome in iron-replete cells. Here, we demonstrate that IRP2 is oxidized and ubiquitinated in cells before degradation. Moreover, iron-dependent oxidation converts IRP2 into a substrate for ubiquitination in vitro. A regulatory pathway is described in which excess iron is sensed by its ability to catalyze site-specific oxidations in IRP2, oxidized IRP2 is ubiquitinated, and ubiquitinated IRP2 subsequently is degraded by the proteasome. Selective targeting and removal of oxidatively modified proteins may contribute to the turnover of many proteins that are degraded by the proteasome.